

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
August 13, 2020

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Joyce Yu, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Jorge A. Garcia, MD, FACP

Chair, Division of Solid Tumor Oncology
George and Edith Richman Distinguished Scientist
Chair
Director, GU Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Christian S. Hinrichs, MD

Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology
Branch
National Cancer Institute
National Institutes of Health (NIH)
Bethesda, Maryland

Philip C. Hoffman, MD

(Chairperson)
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Anthony D. Sung, MD

Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Vice President and Oncology Therapeutic Area Head
Merck Research Laboratories, Oncology Clinical
Research
North Wales, Pennsylvania

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
August 13, 2020

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Nancy J. Bunin, MD

(Afternoon Session Only)
Professor of Pediatrics
University of Pennsylvania
Division of Oncology
Philadelphia, Pennsylvania

Sandra Finestone, PsyD

(Acting Consumer Representative)
Executive Director
Association of Cancer Patient Educators
Irvine, California

Naynesh R. Kamani, MD

(Afternoon Session Only)
Attending Physician
Division of Allergy-Immunology
Children's National Health System
Clinical Professor of Pediatrics
George Washington University School of Medicine
and Health Sciences
Washington, District of Columbia

Sean J. Morrison, PhD

(Morning Session Only)
Director
Children's Medical Center Research Institute
University of Texas Southwestern Medical Center
Dallas, Texas

Diana L. Pearl

(Patient Representative)
Wanship, Utah

Pamela G. Robey, PhD

(Morning Session Only)
Chief, Skeletal Biology Section
National Institute of Dental and Craniofacial
Research
Acting Scientific Investigator, Stem Cell
Characterization Facility
National Institute of Neurological Disorders and
Stroke, NIH
Bethesda, Maryland

Ilyas Singec, MD, PhD

(Morning Session Only)
Director, Stem Cell Translation Laboratory
NIH Regenerative Medicine Program
National Center for Advancing Translational Sciences
Rockville, Maryland

Mark C. Walters, MD

(Afternoon Session Only)
Jordan Family Director Blood and Marrow
Transplantation
University of California San Francisco Benioff
Children's Hospital Oakland
Oakland, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
August 13, 2020

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

(Afternoon Session Only)

Director, Oncology Center of Excellence (OCE)
Acting Director, Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc R. Theoret, MD

(Afternoon Session Only)

Acting Deputy Director
OOD, OND, CDER, FDA

Steven Oh, PhD

(Morning Session Only)

Deputy Director
DCGT, OTAT, CBER, FDA

Bindu George, MD

(Afternoon Session Only)

Branch Chief
Clinical Hematology Branch (CHB)
Division of Clinical Evaluation &
Pharmacology/Toxicology (DCEPT)
OTAT, CBER, FDA

Kristin Baird, MD

(Afternoon Session Only)

Medical Officer
CHB, DCEPT, OTAT, CBER, FDA

Stan Lin, PhD

(Afternoon Session Only)

Mathematical Statistician
Division of Biostatistics (DB)
Office of Biostatistics and Epidemiology (OBE)
CBER, FDA

Wilson Bryan, MD

Director

Office of Tissues and Advances Therapies (OTAT)
Center for Biologics Evaluation and Research
(CBER), FDA

Raj K. Puri, MD, PhD

Director

Division of Cellular & Gene Therapies (DCGT)
Acting Director
Tumor Vaccines and Biotechnology Branch
OTAT, CBER, FDA

Steven R. Bauer, MD

(Morning Session Only)

Branch Chief
Cellular and Tissue Therapy Branch (CTTB)
DCGT, OTAT, CBER, FDA

Donna Przepiorka, MD, PhD

(Afternoon Session Only)

Cross-Discipline Team Leader
Division of Hematologic Malignancies I (DHM I)
OOD, OND, CDER, FDA

Matthew Klinker, PhD

(Morning Session Only)

Biologist
DCGT, OTAT, CBER, FDA

Zhenzhen Xu, PhD

(Afternoon Session Only)

Mathematical Statistician
DB, OBE, CBER, FDA